Restarting Thalidomide-Dexamethasone Regimen in a Post-Abortive Female with Multiple Myeloma: Effective Clinical Response Possible
AbstractNowadays, the prevalence of Multiple Myeloma (MM) seems to have been increasing among young females. Here, we report that thalidomide is contraindicated in pregnant women diagnosed with MM and those desirous of subsequent pregnancy. In this case report, we compared the clinical response of Thalidomide-Dexamethasone therapy in a post-abortive woman with persistently elevated β-hCG levels due to retained products of conception, undergoing hysterectomy later. This case report underlines the clinical significance of age, the effect of Thalidomide-Dexamethasone therapy even after initial discontinuation and the response to high β-hCG levels.
Agaja S, Babalola O, Olawumi H, et al. Unusual Presentations of Multiple Myeloma: Case Report And Review With Focus On Therapeutic And Psychological Aspects. The Internet Journal of Orthopedic Surgery. 2007; 6(2):1-6.
Wang M, Weber DM, Delasalle K, et al. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol. 2005; 79(3):194-7.
Alexanian R, Weber D, Giralt S, et al. Consolidation therapy of multiple myeloma with thalidomide–dexamethasone after intensive chemotherapy. Ann Oncol. 2002: 13(7); 1116-9.
Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001; 98(5):1614-5.
Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24(3):431-6.
van Rhee F, Dhodapkar M, Shaughnessy JD Jr. First thalidomide clinical trial in multiple myeloma: a decade. Blood. 2008; 112(4): 1035-8.